Torrent Pharmaceuticals Share Price
Sector: Biotechnology & Drugs
3295.00 +30.45 (0.93%)
- 1D
- 5D
- 1M
- 3M
- 6M
- 1Y
- 5Y
- MAX
Price Range
Today’s Low
3252
Today’s High
3311.10
52 Week Low
2573.40
52 Week High
3589.95
3307.00 +40.20 (1.23%)
- 1D
- 5D
- 1M
- 3M
- 6M
- 1Y
- 5Y
- MAX
Price Range
Today’s Low
3250
Today’s High
3309
52 Week Low
2570.45
52 Week High
3590.70
Key Metrics
- Market Cap (In Cr) 111524.72
- Beta 0.6
- Div. Yield (%) 0.98
- P/B 16.13
- TTM P/E 61.06
- Peg Ratio 6.07
- Sector P/E 24.5
- Open Price 3289.9
- Prev Close 3264.55
Torrent Pharmaceuticals Analysis
Price Analysis
-
1 Week4%
-
3 Months8.39%
-
6 Month5.3%
-
YTD-2.78%
-
1 Year20.99%
Risk Meter
- 24% Low risk
- 24% Moderate risk
- 24% Balanced Risk
- 24% High risk
- 24% Extreme risk
Recos
- Strong Sell
- Sell
- Hold
- Buy
- Strong Buy
Analysts' Views
- Ratings
- Current
- 1 W Ago
- 1 M Ago
- 3 M Ago
- Strong Buy
- 4
- 4
- 4
- 4
- Buy
- 9
- 9
- 9
- 10
- Hold
- 7
- 7
- 7
- 7
- Sell
- 4
- 4
- 4
- 4
- Strong Sell
- 1
- 1
- 1
- 1
- Total
- 25
- 25
- 25
- 26
Torrent Pharmaceuticals News
Q4 results today: Tata Power, Eicher Motors, Lupin, Shree Cements on May 14
1 min read . 14 May 2025Rupak De suggests buy or sell strategy for THESE stocks in F&O segment
3 min read . 21 Apr 2025India's Torrent Pharma misses Q3 profit estimates, hurt by insulin plant closure
1 min read . 24 Jan 2025Torrent Pharmaceuticals Financials
- INCOME
- BALANCE SHEET
- Cashflow
- Period
- 2024
- Total Revenue
- 10727.84
- Selling/ General/ Admin Expenses Total
- 3965.68
- Depreciation/ Amortization
- 795.3
- Other Operating Expenses Total
- 582.05
- Total Operating Expense
- 8168.46
- Operating Income
- 2559.38
- Net Income Before Taxes
- 2352.11
- Net Income
- 1656.38
- Diluted Normalized EPS
- 47.37
- Period
- 2024
- Total Assets
- 15060.58
- Total Liabilities
- 8204.43
- Total Equity
- 6856.15
- Tangible Book Valueper Share Common Eq
- 57.18
- Period
- 2024
- Cashfrom Operating Activities
- 3266.08
- Cashfrom Investing Activities
- -167.9
- Cashfrom Financing Activities
- -2779.64
- Net Changein Cash
- 326.61
- Period
- 2023
- Total Revenue
- 9620.15
- Selling/ General/ Admin Expenses Total
- 3447.24
- Depreciation/ Amortization
- 702.03
- Other Operating Expenses Total
- 471.9
- Total Operating Expense
- 7484.69
- Operating Income
- 2135.46
- Net Income Before Taxes
- 1847.16
- Net Income
- 1245.23
- Diluted Normalized EPS
- 36.45
- Period
- 2023
- Total Assets
- 15011.85
- Total Liabilities
- 8813.78
- Total Equity
- 6198.07
- Tangible Book Valueper Share Common Eq
- 22.78
- Period
- 2023
- Cashfrom Operating Activities
- 2426.96
- Cashfrom Investing Activities
- -2415.31
- Cashfrom Financing Activities
- 77.36
- Net Changein Cash
- 110.13
- Period
- 2022
- Total Revenue
- 8508.04
- Selling/ General/ Admin Expenses Total
- 3060.61
- Depreciation/ Amortization
- 661.93
- Other Operating Expenses Total
- 440.04
- Total Operating Expense
- 7223.63
- Operating Income
- 1284.41
- Net Income Before Taxes
- 1225.91
- Net Income
- 777.18
- Diluted Normalized EPS
- 32.05
- Period
- 2022
- Total Assets
- 13099.84
- Total Liabilities
- 7146.89
- Total Equity
- 5952.95
- Tangible Book Valueper Share Common Eq
- 63.45
- Period
- 2022
- Cashfrom Operating Activities
- 1802.99
- Cashfrom Investing Activities
- -196.63
- Cashfrom Financing Activities
- -1781.05
- Net Changein Cash
- -174.16
- Period
- 2021
- Total Revenue
- 8004.83
- Selling/ General/ Admin Expenses Total
- 2822.98
- Depreciation/ Amortization
- 657.31
- Other Operating Expenses Total
- 435.69
- Total Operating Expense
- 6176.94
- Operating Income
- 1827.89
- Net Income Before Taxes
- 1526.26
- Net Income
- 1251.88
- Diluted Normalized EPS
- 37
- Period
- 2021
- Total Assets
- 14074.65
- Total Liabilities
- 8237.48
- Total Equity
- 5837.17
- Tangible Book Valueper Share Common Eq
- 44.67
- Period
- 2021
- Cashfrom Operating Activities
- 2005.35
- Cashfrom Investing Activities
- -449.42
- Cashfrom Financing Activities
- -1650.79
- Net Changein Cash
- -89.26
- Period
- 2020
- Total Revenue
- 7939.31
- Selling/ General/ Admin Expenses Total
- 2908.94
- Depreciation/ Amortization
- 651.51
- Other Operating Expenses Total
- 514.98
- Total Operating Expense
- 6423.33
- Operating Income
- 1515.98
- Net Income Before Taxes
- 1186.57
- Net Income
- 1024.72
- Diluted Normalized EPS
- 28.79
- Period
- 2020
- Total Assets
- 14009.74
- Total Liabilities
- 9186.52
- Total Equity
- 4823.22
- Tangible Book Valueper Share Common Eq
- 3.19
- Period
- 2020
- Cashfrom Operating Activities
- 1392.91
- Cashfrom Investing Activities
- 198.61
- Cashfrom Financing Activities
- -1549.04
- Net Changein Cash
- 73.06
- Period
- 2019
- Total Revenue
- 7672.8
- Selling/ General/ Admin Expenses Total
- 2897.84
- Depreciation/ Amortization
- 614.39
- Other Operating Expenses Total
- 470.23
- Total Operating Expense
- 6664.44
- Operating Income
- 1008.36
- Net Income Before Taxes
- 561.66
- Net Income
- 436.28
- Diluted Normalized EPS
- 21.16
- Period
- 2019
- Total Assets
- 14120.92
- Total Liabilities
- 9396.57
- Total Equity
- 4724.35
- Tangible Book Valueper Share Common Eq
- -10.65
- Period
- 2019
- Cashfrom Operating Activities
- 1798.08
- Cashfrom Investing Activities
- -241.28
- Cashfrom Financing Activities
- -1314.45
- Net Changein Cash
- 238.02
- Period
- 2024-12-31
- Total Revenue
- 2809
- Selling/ General/ Admin Expenses Total
- 549
- Depreciation/ Amortization
- 199
- Other Operating Expenses Total
- 673
- Total Operating Expense
- 2094
- Operating Income
- 715
- Net Income Before Taxes
- 691
- Net Income
- 503
- Diluted Normalized EPS
- 14.88
- Period
- 2024-12-31
- Period
- 2024-12-31
- Period
- 2024-09-30
- Total Revenue
- 2889
- Selling/ General/ Admin Expenses Total
- 543
- Depreciation/ Amortization
- 198
- Other Operating Expenses Total
- 729
- Total Operating Expense
- 2148
- Operating Income
- 741
- Net Income Before Taxes
- 661
- Net Income
- 453
- Diluted Normalized EPS
- 13.37
- Period
- 2024-09-30
- Total Assets
- 15088
- Total Liabilities
- 7584
- Total Equity
- 7504
- Tangible Book Valueper Share Common Eq
- 83.65
- Period
- 2024-09-30
- Cashfrom Operating Activities
- 1683
- Cashfrom Investing Activities
- -159
- Cashfrom Financing Activities
- -1215
- Net Changein Cash
- 311
- Period
- 2024-06-30
- Total Revenue
- 2859
- Selling/ General/ Admin Expenses Total
- 550
- Depreciation/ Amortization
- 197
- Other Operating Expenses Total
- 711
- Total Operating Expense
- 2152
- Operating Income
- 707
- Net Income Before Taxes
- 656
- Net Income
- 457
- Diluted Normalized EPS
- 13.51
- Period
- 2024-06-30
- Period
- 2024-06-30
- Period
- 2024-03-31
- Total Revenue
- 2744.84
- Selling/ General/ Admin Expenses Total
- 486.4
- Depreciation/ Amortization
- 203.27
- Other Operating Expenses Total
- 696.58
- Total Operating Expense
- 2065.46
- Operating Income
- 679.38
- Net Income Before Taxes
- 631.11
- Net Income
- 449.38
- Diluted Normalized EPS
- 13.26
- Period
- 2024-03-31
- Total Assets
- 15060.58
- Total Liabilities
- 8204.43
- Total Equity
- 6856.15
- Tangible Book Valueper Share Common Eq
- 57.18
- Period
- 2024-03-31
- Cashfrom Operating Activities
- 3266.08
- Cashfrom Investing Activities
- -167.9
- Cashfrom Financing Activities
- -2779.64
- Net Changein Cash
- 326.61
- Period
- 2023-12-31
- Total Revenue
- 2732
- Selling/ General/ Admin Expenses Total
- 496
- Depreciation/ Amortization
- 213
- Other Operating Expenses Total
- 670
- Total Operating Expense
- 2076
- Operating Income
- 656
- Net Income Before Taxes
- 631
- Net Income
- 443
- Diluted Normalized EPS
- 11.27
- Period
- 2023-12-31
- Period
- 2023-12-31
Forecast
Income Sheet (In Cr)
Net Income Vs Revenue
Returns Metrics (In Cr)
ROA Vs ROE
Forecast
Balance Sheet
Asset vs Liability
Forecast
Cash Flow
Operating vs Investing
Torrent Pharmaceuticals Technical
Moving Average
SMA
- 5 Day3248.66
- 10 Day3240.61
- 20 Day3264.13
- 50 Day3192.65
- 100 Day3215.8
- 300 Day3271.52
Torrent Pharmaceuticals Peers
- Price
- Ratio
- Name
- Latest Price
- Change
- % Change
- 52W High
- 52W Low
- Mkt. Cap
- Divis Laboratories
- 6654.1
- 372.75
- 5.93
- 6448.75
- 3725.55
- 176112.25
- Cipla
- 1499.1
- -0.6
- -0.04
- 1702
- 1310.05
- 121073.37
- Torrent Pharmaceuticals
- 3295
- 30.45
- 0.93
- 3589.95
- 2573.4
- 111524.72
- Dr Reddys Laboratories
- 1225.1
- -5.4
- -0.44
- 1420.2
- 1025.9
- 102377.72
- Lupin
- 2061.75
- -6.6
- -0.32
- 2403.45
- 1493.75
- 94142.92
- Name
- P/E (X)
- P/B (X)
- ROE %
- OPM
- Divis Laboratories
- 104
- 12.28
- 18.97
- 26.38
- Cipla
- 22.99
- 3.88
- 15.18
- 14.74
- Torrent Pharmaceuticals
- 68.96
- 16.13
- 20.64
- 13.18
- Dr Reddys Laboratories
- 18.11
- 3.05
- 17.62
- 15.81
- Lupin
- 28.85
- 5.49
- 7.86
- 5.95
Torrent Pharmaceuticals Shareholding
Shareholding Pattern
Shareholding Trend
Shareholding(%) v/s Date
Corporate Actions
- Board Meeting
- AGM
- Dividends
- Bonus
- Split
- Rights
- Meeting Date
- Purpose
- 20-May-25
- Audited Results, Final Dividend & Others
- 24-Jan-25
- Quarterly Results & Others
- 25-Oct-24
- Quarterly Results
- 23-Jul-24
- Quarterly Results
- 24-May-24
- Audited Results & Final Dividend
- 02-Feb-24
- Quarterly Results & Interim Dividend
- 23-Oct-23
- Quarterly Results
- 07-Aug-23
- Quarterly Results
- 30-May-23
- Audited Results & Final Dividend
- 25-Jan-23
- Quarterly Results & Interim Dividend
- Meeting Date
- Announced on
- Purpose
- 23-Jul-24
- 24-May-24
- AGM
- 29-Nov-23
- 26-Oct-23
- POM
- 07-Aug-23
- 20-Jun-23
- AGM
- 29-Jul-22
- 25-May-22
- AGM
- 27-Jul-21
- 30-Jun-21
- AGM
- Announced on
- Record Date
- Ex-Dividend
- Dividend Value
- 14-Jan-25
- 01-Feb-25
- 31-Jan-25
- 26
- 24-May-24
- 21-Jun-24
- 21-Jun-24
- 6
- 12-Jan-24
- 12-Feb-24
- 12-Feb-24
- 22
- 30-May-23
- 23-Jun-23
- 23-Jun-23
- 8
- 12-Jan-23
- 03-Feb-23
- 03-Feb-23
- 14
- 25-May-22
- 06-Jun-22
- 03-Jun-22
- 8
- 26-May-22
- 06-Jun-22
- 03-Jun-22
- 15
- 10-Jan-22
- 03-Feb-22
- 02-Feb-22
- 25
- 18-May-21
- 18-Jun-21
- 17-Jun-21
- 15
- 18-Jan-21
- 16-Feb-21
- 15-Feb-21
- 20
- Announced on
- Record Date
- Ex-Bonus
- Description
- 25-May-22
- 11-Jul-22
- 08-Jul-22
- Bonus issue of equity shares in the ratio of 1:1 of Rs. 5/-.

